A US case-control study to estimate infant group B streptococcal disease serological thresholds of risk-reduction
Abstract Maternal vaccines to prevent infant Group B Streptococcus (GBS) disease have progressed through phase II development and may be licensed based on immunologic endpoints, which have yet to be approved by regulatory authorities. Here we present a multistate case control study to characterize t...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Nature Portfolio
2025-10-01
|
| Seri Bilgileri: | Nature Communications |
| Online Erişim: | https://doi.org/10.1038/s41467-025-64324-y |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|
